ArticleBMC neurology2026
Retinal hemodynamic and caliber biomarkers for the assessment of cerebral small vessel disease burden: insights from fundus fluorescein angiography.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundRetinal microvasculature serves as a promising window to assess cerebral small vessel disease (CSVD). However, the association between comprehensive fundus fluorescein angiography (FFA) biomarkers and the total CSVD burden score remains to be fully elucidated. AIMES: To investigate the relationship between the total CSVD burden score and FFA-derived retinal biomarkers, and to identify independent retinal indicators for evaluating CSVD severity.
methodsThis retrospective study enrolled 120 patients. The CSVD burden score was evaluated based on lacunes of presumed vascular origin, white matter hyperintensities, enlarged perivascular spaces, and cerebral microbleeds. FFA parameters included dynamic hemodynamic indicators (arm-retinal circulation time [ARCT], retinal circulation time [V1-ARCT], retinal venous transit time [V2-V1]) and static vascular caliber indicators (central retinal artery equivalent [CRAE], central retinal vein equivalent [CRVE], arteriolar-to-venular ratio [AVR]), as well as arteriovenous nicking and vascular leakage. Correlation and multivariable regression analyses were performed.
resultsAcross CSVD burden groups, significant differences were detected in age, hypertension, hyperlipidemia, key neuroimaging markers, ARCT, V1-ARCT, CRAE, CRVE, and AVR, whereas gender, diabetes, arteriovenous nicking, vascular leakage, and V2-V1 showed no significant differences. Spearman analysis showed that the CSVD burden score was negatively correlated with CRAE and AVR, and positively correlated with CRVE and V1-ARCT. Multivariable analysis identified CRAE, CRVE, and V1-ARCT as independent factors associated with the CSVD burden score: lower CRAE, higher CRVE, and prolonged V1-ARCT were related to higher CSVD burden.
conclusionStatic vascular caliber (CRAE, CRVE) and dynamic retinal circulation time (V1-ARCT) are independently associated with CSVD burden. The combined use of these FFA biomarkers provides a promising tool for the early assessment and noninvasive monitoring of CSVD, supporting further clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.